E-ISSN 2534-9821
 

Case Report 


Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab

Timothy Patrick McCann, Hatem Elabd, Stephen P Beerman.

Abstract
Introduction: Nivolumab is an immune checkpoint inhibitor (ICI) in a class of immunomodulators used to treat various cancers, including melanoma. Here we present ICI-related cardiomyopathy leading to patient death.
Case Report: An 88-year-old female receiving therapy for metastatic melanoma with immune checkpoint inhibitor Nivolumab presented with acute hypoxic respiratory failure secondary to new onset acute combined systolic and diastolic heart failure. She had no known cardiac history and was on minimal medication before the presentation. After extensive workup, including pleural fluid analysis, a cardiac magnetic resonance, and left heart catheterization, no other cause could be attributed to her cardiac dysfunction other than an adverse medication event due to immunomodulation therapy with Nivolumab.
Discussion: Cardiomyopathy is a rare but potentially life-threatening complication of ICI therapy and should be considered when discussing treatment modalities with patients, especially in high-risk populations.

Key words: Nivolumab, immune checkpoint inhibitor, cardiomyopathy, melanoma


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Timothy Patrick McCann
Articles by Hatem Elabd
Articles by Stephen P Beerman
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep. 2022; 6(14): 44-47. doi:10.5455/IJMRCR.172-1650130669


Web Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. https://www.mdpub.net/?mno=18345 [Access: November 20, 2022]. doi:10.5455/IJMRCR.172-1650130669


AMA (American Medical Association) Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep. 2022; 6(14): 44-47. doi:10.5455/IJMRCR.172-1650130669



Vancouver/ICMJE Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep. (2022), [cited November 20, 2022]; 6(14): 44-47. doi:10.5455/IJMRCR.172-1650130669



Harvard Style

McCann, T. P., Elabd, . H. & Beerman, . S. P. (2022) Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep, 6 (14), 44-47. doi:10.5455/IJMRCR.172-1650130669



Turabian Style

McCann, Timothy Patrick, Hatem Elabd, and Stephen P Beerman. 2022. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. International Journal of Medical Reviews and Case Reports, 6 (14), 44-47. doi:10.5455/IJMRCR.172-1650130669



Chicago Style

McCann, Timothy Patrick, Hatem Elabd, and Stephen P Beerman. "Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab." International Journal of Medical Reviews and Case Reports 6 (2022), 44-47. doi:10.5455/IJMRCR.172-1650130669



MLA (The Modern Language Association) Style

McCann, Timothy Patrick, Hatem Elabd, and Stephen P Beerman. "Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab." International Journal of Medical Reviews and Case Reports 6.14 (2022), 44-47. Print. doi:10.5455/IJMRCR.172-1650130669



APA (American Psychological Association) Style

McCann, T. P., Elabd, . H. & Beerman, . S. P. (2022) Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. International Journal of Medical Reviews and Case Reports, 6 (14), 44-47. doi:10.5455/IJMRCR.172-1650130669